10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x    Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2015

o    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number: 1-8351

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	31-0791746
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
255 E. Fifth Street, Suite 2600, Cincinnati, Ohio	45202
(Address of principal executive offices)	(Zip code)
(513) 762-6690 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Amount	Date
Capital Stock $1 Par Value	16,919,487 Shares	June 30, 2015

-1-

CHEMED CORPORATION AND

SUBSIDIARY COMPANIES

Index

	Page No.
PART I.    FINANCIAL INFORMATION:
Item 1.  Financial Statements
Unaudited Consolidated Balance Sheet - June 30, 2015 and December 31, 2014	3
Unaudited Consolidated Statement of Income - Three and six months ended June 30, 2015 and 2014		4
Unaudited Consolidated Statement of Cash Flows - Six months ended June 30, 2015 and 2014		5
Notes to Unaudited Consolidated Financial Statements		6
Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations		15
Item 3.  Quantitative and Qualitative Disclosures about Market Risk		32
Item 4.  Controls and Procedures		32
PART II.   OTHER INFORMATION
Item 1.    Legal Proceedings		32
Item 1A. Risk Factors		32
Item 2.    Unregistered Sales of Equity Securities and Use of  Proceeds		33
Item 3.    Defaults Upon Senior Securities		33
Item 4.    Mine Safety Disclosures		33
Item 5.    Other Information		33
Item 6.    Exhibits		34
EX – 31.1
EX – 31.2
EX – 31.3
EX – 32.1
EX – 32.2
EX – 32.3
EX – 101.INS
EX – 101.SCH
EX – 101.CAL
EX – 101.DEF
EX – 101.LAB
EX – 101.PRE

-2-

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
UNAUDITED CONSOLIDATED BALANCE SHEET
(in thousands, except share and per share data)
	June 30, 2015			December 31, 2014
ASSETS
Current assets
Cash and cash equivalents	$	32,705		$	14,132
Accounts receivable less allowances of $17,156 (2014 - $14,728)		119,116			124,607
Inventories		6,250			6,168
Current deferred income taxes		16,432			15,414
Prepaid income taxes		3,474			2,787
Prepaid expenses		12,069			11,456
Total current assets		190,046			174,564
Investments of deferred compensation plans		51,940			49,147
Properties and equipment, at cost, less accumulated depreciation of $190,227 (2014 - $185,735)		107,556			105,336
Identifiable intangible assets less accumulated amortization of $33,031 (2014 - $32,772)		55,979			56,027
Goodwill		472,546			466,722
Other assets		7,216			8,136
Total Assets	$	885,283		$	859,932
LIABILITIES
Current liabilities
Accounts payable	$	39,327		$	46,849
Current portion of long-term debt		7,500			6,250
Income taxes		20			5,818
Accrued insurance		42,589			40,814
Accrued compensation		48,909			50,718
Accrued legal		1,815			753
Other current liabilities		21,752			24,352
Total current liabilities		161,912			175,554
Deferred income taxes		28,280			29,945
Long-term debt		152,500			141,250
Deferred compensation liabilities		52,051			48,684
Other liabilities		12,742			13,143
Total Liabilities		407,485			408,576
Commitments and contingencies
STOCKHOLDERS' EQUITY
Capital stock - authorized 80,000,000 shares $1 par; issued 33,619,982 shares (2014 - 33,337,297 shares)		33,620			33,337
Paid-in capital		562,654			538,845
Retained earnings		815,229			771,176
Treasury stock - 16,800,313 shares (2014 - 16,446,572)		(936,056	)		(894,285	)
Deferred compensation payable in Company stock		2,351			2,283
Total Stockholders' Equity		477,798			451,356
Total Liabilities and Stockholders' Equity	$	885,283		$	859,932
See accompanying notes to unaudited consolidated financial statements.

-3-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
UNAUDITED CONSOLIDATED STATEMENT OF INCOME
(in thousands, except per share data)
	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Service revenues and sales	$	381,921		$	360,182		$	758,573		$	718,482
Cost of services provided and goods sold (excluding depreciation)		270,663			257,007			539,548			514,826
Selling, general and administrative expenses		57,994			53,649			116,582			109,320
Depreciation		8,082			7,272			16,114			14,421
Amortization		582			735			1,158			1,744
Total costs and expenses		337,321			318,663			673,402			640,311
Income from operations		44,600			41,519			85,171			78,171
Interest expense		(969	)		(2,429	)		(1,938	)		(6,244	)
Other income - net		536			756			1,099			1,572
Income before income taxes		44,167			39,846			84,332			73,499
Income taxes		(17,192	)		(15,483	)		(32,820	)		(28,562	)
Net income	$	26,975		$	24,363		$	51,512		$	44,937
Earnings Per Share
Net income	$	1.60		$	1.41		$	3.05		$	2.59
Average number of shares outstanding		16,880			17,236			16,872			17,374
Diluted Earnings Per Share
Net income	$	1.55		$	1.36		$	2.96		$	2.48
Average number of shares outstanding		17,419			17,880			17,419			18,097
Cash Dividends Per Share	$	0.22		$	0.20		$	0.44		$	0.40
See accompanying notes to unaudited consolidated financial statements.

-4-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
	Six Months Ended June 30,
	2015			2014
Cash Flows from Operating Activities
Net income	$	51,512		$	44,937
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization		17,272			16,165
Deferred income taxes		(2,783	)		6,180
Provision for uncollectible accounts receivable		7,734			6,449
Amortization of discount on convertible notes		-			3,392
Stock option expense		2,787			2,453
Amortization of debt issuance costs		262			564
Noncash long-term incentive compensation		2,391			986
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Increase in accounts receivable		(2,182	)		(6,782	)
Increase in inventories		(78	)		(153	)
Increase in prepaid expenses		(507	)		(3,301	)
Decrease in accounts payable and other current liabilities		(1,314	)		(33,584	)
Increase/(decrease) in income taxes		(2,384	)		7,224
Increase in other assets		(2,229	)		(2,748	)
Increase in other liabilities		2,966			4,644
Excess tax benefit on share-based compensation		(3,998	)		(1,866	)
Other sources		189			553
Net cash provided by operating activities		69,638			45,113
Cash Flows from Investing Activities
Capital expenditures		(18,846	)		(19,454	)
Business combinations, net of cash acquired		(6,614	)		(250	)
Other sources		395			192
Net cash used by investing activities		(25,065	)		(19,512	)
Cash Flows from Financing Activities
Proceeds from revolving line of credit		103,200			245,500
Payments on revolving line of credit		(88,200	)		(185,500	)
Payments on other long-term debt		(2,500	)		(186,956	)
Proceeds from other long-term debt		-			100,000
Purchases of treasury stock		(29,762	)		(58,493	)
Proceeds from exercise of stock options		8,044			16,092
Dividends paid		(7,459	)		(6,757	)
Capital stock surrendered to pay taxes on stock-based compensation		(5,876	)		(3,543	)
Retirement of warrants		-			(2,645	)
Excess tax benefit on share-based compensation		3,998			1,866
Debt issuance costs		-			(939	)
Decrease in cash overdrafts payable		(6,791	)		(479	)
Other uses		(654	)		(252	)
Net cash used by financing activities		(26,000	)		(82,106	)
Increase/(Decrease) in Cash and Cash Equivalents		18,573			(56,505	)
Cash and cash equivalents at beginning of year		14,132			84,418
Cash and cash equivalents at end of period	$	32,705		$	27,913
See accompanying notes to unaudited consolidated financial statements.

-5-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

Notes to Unaudited Consolidated Financial Statements

1.   Basis of Presentation

As used herein, the terms "We," "Company" and "Chemed" refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries.

We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X.  Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 2014 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP.  However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows.  These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014.

2.   Revenue Recognition

Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed. Generally, this occurs when services are provided or products are delivered. VITAS recognizes revenue at the estimated realizable amount due from third-party payers. Medicare payments are subject to certain limitations, as described below.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”).  Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions.  However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to patient revenue.

During the second quarter of 2015, no Medicare cap was recorded.

During the first six months ended June 30, 2015, we recorded a $165,000 Medicare cap reversal of amounts recorded in the fourth quarter of 2014 for one program’s projected 2015 measurement period liability. The fourth quarter of 2014 was part of the 2015 Medicare cap year.

Shown below is the Medicare cap liability activity for the fiscal periods ended (in thousands):

	June 30,
	2015			2014
Beginning balance January 1,	$	6,112		$	8,260
2015 measurement period		(165	)		-
2014 measurement period		-			(704	)
Payments		(4,782	)		(3,439	)
Ending balance June 30,	$	1,165		$	4,117

Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient does not have the financial wherewithal to make payment.  There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care.  The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care.  The cost of charity care is as follows (in thousands):

-6-

Three months ended June 30,				Six months ended June 30,
2015		2014		2015		2014
$	1,885	$	1,931	$	3,859	$	3,630

3.   Segments

Service revenues and sales and after-tax earnings by business segment are as follows (in thousands):

	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Service Revenues and Sales
VITAS	$	276,460		$	264,026		$	546,073		$	524,438
Roto-Rooter		105,461			96,156			212,500			194,044
Total	$	381,921		$	360,182		$	758,573		$	718,482
After-tax Earnings
VITAS	$	21,800		$	20,892		$	41,116		$	39,051
Roto-Rooter		12,153			10,719			24,161			20,751
Total		33,953			31,611			65,277			59,802
Corporate		(6,978	)		(7,248	)		(13,765	)		(14,865	)
Net income	$	26,975		$	24,363		$	51,512		$	44,937

We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”.

4.  Earnings per Share

Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding.  Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):

		Net Income
For the Three Months Ended June 30,		Income		Shares	Earnings per Share
2015
	Earnings	$	26,975	16,880	$	1.60
	Dilutive stock options		-	390
	Nonvested stock awards		-	149
	Diluted earnings	$	26,975	17,419	$	1.55
2014
	Earnings	$	24,363	17,236	$	1.41
	Dilutive stock options		-	376
	Nonvested stock awards		-	147
	Conversion of notes		-	121
	Diluted earnings	$	24,363	17,880	$	1.36

-7-

			Net Income
For the Six Months Ended June 30,		Income		Shares	Earnings per Share
2015
	Earnings	$	51,512	16,872	$	3.05
	Dilutive stock options		-	395
	Nonvested stock awards		-	152
	Diluted earnings	$	51,512	17,419	$	2.96
2014
	Earnings	$	44,937	17,374	$	2.59
	Dilutive stock options		-	374
	Nonvested stock awards		-	147
	Conversion of Notes		-	202
	Diluted earnings	$	44,937	18,097	$	2.48

For the three and six-month period ended June 30, 2015, 411,000 stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.  For the three and six-month period ended June 30, 2014 no stock options were so excluded.

For the three and six-months of 2014 diluted earnings per share was impacted by the issuance of 249,000 shares of capital stock under the conversion feature of our 1.875% Senior Convertible Notes (the “Notes”) on the May 15, 2014 maturity date.  Assuming these shares were issued April 1, 2014 increases average diluted shares outstanding for the second quarter of 2014 by 121,000 shares.  Similarly, the dilutive impact of this conversion feature for the first six months of 2014 was 202,000.

5.   Long-Term Debt

On June 30, 2014, we replaced our existing credit agreement with the Third Amended and Restated Credit Agreement (“2014 Credit Agreement”).   Terms of the 2014 Credit Agreement consist of a five-year, $350 million revolving credit facility and a $100 million term loan. The 2014 Credit Agreement has a floating interest rate that is currently LIBOR plus 113 basis points.

The debt outstanding as of June 30, 2015 consists of the following:

Revolver	$	65,000
Term loan		95,000
Total		160,000
Current portion of term and revolving loan		(7,500)
Long-term debt	$	152,500

Scheduled principal payments of the term loan are as follows:

2015	$	3,750
2016		7,500
2017		8,750
2018		10,000
2019		65,000
	$	95,000

-8-

The 2014 Credit Agreement contains the following quarterly financial covenants:

Description	Requirement
Leverage Ratio (Consolidated Indebtedness/Consolidated  Adj. EBITDA)	< 3.50 to 1.00
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges)	> 1.50 to 1.00
Annual Operating Lease Commitment	< $50.0 million

We are in compliance with all debt covenants as of June 30, 2015. We have issued $36.6 million in standby letters of credit as of June 30, 2015 for insurance purposes.  Issued letters of credit reduce our available credit under the 2014 Credit Agreement.  As of June 30, 2015, we have approximately $248.4 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility.

6.   Other Income – Net

Other income -- net comprises the following (in thousands):

	Three months ended June 30,							Six months ended June 30,
	2015				2014			2015			2014
Market value gains on assets held in deferred
compensation trust		$	498		$	650		$	1,448		$	1,812
Loss on disposal of property and equipment			(63	)		(48	)		(15	)		(326	)
Interest income - net			86			58			130			8
Other - net			15			96			(464	)		78
Total other income - net		$	536		$	756		$	1,099		$	1,572

 7.   Stock-Based Compensation Plans

On May 18, 2015, the Compensation/Incentive Committee of the Board of Directors (“CIC”) approved a grant of 32,550 shares of restricted stock to certain key employees.  The restricted shares vest ratably over three years from the date of issuance.  The cumulative compensation expense related to the restricted stock award is $4.0 million and will be recognized over the three-year vesting period.  We assumed no forfeitures in determining the cumulative compensation expense of the grant.

On February 20, 2015, the (“CIC”) granted 10,761 Performance Stock Units (“PSUs”) contingent upon the achievement of certain total shareholders return (“TSR”) targets as compared to the TSR of a group of peer companies for the three-year period ending December 31, 2017, the date at which such awards vest.  The cumulative compensation cost of the TSR-based PSU award to be recorded over the three year service period is $1.5 million.

On February 20, 2015, the CIC also granted 10,761 PSUs contingent upon the achievement of certain earnings per share (“EPS”) targets for the three-year period ending December 31, 2017.  At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records that expense over the service period of the award.  We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three year service period is $1.6 million.

-9-

8.   Independent Contractor Operations

The Roto-Rooter segment sublicenses with 69 independent contractors to operate certain plumbing repair and drain cleaning businesses in lesser-populated areas of the United States and Canada.  We had notes receivable from our independent contractors as of June 30, 2015 totaling $1.6 million (December 31, 2014 - $1.6 million).  In most cases these loans are fully or partially secured by equipment owned by the contractor.  The interest rates on the loans range from 0% to 7% per annum and the remaining terms of the loans range from 2 months to 5 years at June 30, 2015.  We recorded the following from our independent contractors (in thousands):

	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Revenues		$	9,527		$	9,190		$	18,991		$	18,213
Pretax profits			5,661			5,235			11,218			10,395

9.   Retirement Plans

All of the Company’s plans that provide retirement and similar benefits are defined contribution plans.  These expenses include the impact of market gains and losses on assets held in deferred compensation plans.  Expenses for the Company’s pension and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):

Three months ended June 30,				Six months ended June 30,
2015		2014		2015		2014
$	2,991	$	3,324	$	7,178	$	7,222

10.  Legal and Regulatory Matters

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

Regulatory Matters and Litigation

In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas,  United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a then registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

-10-

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”).  Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action.  The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS.  The defendants filed a motion to dismiss on September 24, 2013.  The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014. 

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California, United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government partially intervened in Gonzales.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.  

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the Spottiswood,  Urick, and  Gonzales complaints with the 2013 Action.  As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes.  The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators.  The Spottiswood relator filed an action under the Illinois False Claims Act, The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014.  The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters.  In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.  In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

The costs incurred related to U.S. v. Vitas and related regulatory matters were $1.4 million and $410,000 for the quarters ended June 30, 2015 and 2014, respectively. For the six months ended June 30, 2015 and 2014, the net costs were $2.7 million and $1.2 million respectively.

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance.  On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al., No. 13 Civ. 1854 (LPS) (D. Del.).  It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant.  Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare.  The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

-11-

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al., No. 13 Civ. 833 (MDB) (S.D. Ohio).  She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant.  Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls.  The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants.  The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole.  Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6).  On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware.  Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke.

On October 15, 2014, Plaintiff KBC filed a motion to consolidate KBC with North.  On February 2, 2015 the court granted the motion for consolidation in full, appointing Plaintiff KBC the sole lead plaintiff and its counsel, the sole lead and liaison counsel.  The court ordered that both cases will proceed under the caption In re Chemed Corp. Shareholder and Derivative Litigation, No. 13 Civ. 1854 (LPS) (CJB) (D. Del.).  Plaintiff KBC has designated its pending complaint as the operative complaint in the consolidated proceedings.  Defendants have renewed their motion to dismiss the claims and allegations.

The Company intends to defend vigorously against the allegations in each of the above lawsuits.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity.  Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

11.   Concentration of Risk

VITAS has pharmacy services agreements ("Agreements") with Omnicare, Inc. and its subsidiaries (“OCR”) whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR.  The Agreements renew automatically for three-year terms.  Either party may cancel the Agreements at the end of any term by giving 30 days prior written notice.  VITAS made purchases from OCR of $9.5 million and $8.8 million for the three months ended June 30, 2015 and 2014, respectively.  VITAS made purchases from OCR of $18.7 million and $17.7 million for the six months ended June 30, 2015 and 2014, respectively. For the three and six month periods ending June 30, 2015 and 2014, respectively, purchases from this vendor exceed 90% of all pharmacy services used by VITAS.

12.   Cash Overdrafts and Cash Equivalents

Included in accounts payable at June 30, 2015 is cash overdrafts payable of $3.7 million (December 31, 2014 - $10.5 million).

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds.  We had $66,000 in cash equivalents as of June 30, 2015.  There was $80,000 in cash equivalents as of December 31, 2014.  The weighted average rate of return for our cash equivalents was 0.08% at June 30, 2015 and 0.06% at December 31, 2014.

-12-

13.   Financial Instruments

FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements.  Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities.  Level 2 measurements use significant other observable inputs.  Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions.  In recording the fair value of assets and liabilities, companies must use the most reliable measurement available.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of June 30, 2015 (in thousands):

			Fair Value Measure
	Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable  Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	51,940	$	51,940	$	-	$	-
Long-term debt		160,000		-		160,000		-

For the mutual fund investments carrying value is fair value.  All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of  December 31, 2014 (in thousands):

			Fair Value Measure
	Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	49,147	$	49,147	$	-	$	-
Long-term debt		147,500		-		147,500		-

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments.

14.   Capital Stock Repurchase Plan Transactions

We repurchased the following capital stock for the three and six months ended June 30, 2015 and 2014:

	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Shares repurchased			250,000			300,000			250,000			682,934
Weighted average price per share		$	119.05		$	85.04		$	119.05		$	85.65

In March 2015, the Board of Directors authorized an additional $100 million for stock repurchase under Chemed’s existing share repurchase program. We currently have $82.0 million of authorization remaining under this share repurchase plan.

-13-

15.   Recent Accounting Statements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers” which provides additional guidance to clarify the principles for recognizing revenue.  The standard will also be used to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide more useful information to users through improved disclosure requirements, and simplify the preparation of financial statements.  The guidance is effective for fiscal years beginning after December 15, 2017.  We are currently evaluating the impact of this ASU on our existing revenue recognition policies and disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ASU No. 2014-15 - Presentation of Financial Statements-Going Concern”.   ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for us for the annual period ending December 31, 2016 and interim periods thereafter. We do not expect the adoption of this standard to have a material impact on our consolidated financial position, results of operations or cash flows.

In April 2015, the FASB issued Accounting Standards Update No. 2015-03, “ASU No. 2015-03 – Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”.  ASU 2015-03 is intended to simplify the presentation of debt issuance costs.  Under the new guidance, debt issuance costs will be presented as a direct deduction from the carrying value of the associated debt, consistent with the existing presentation of a debt discount.  This guidance is effective for us for the annual period beginning after December 15, 2015.  We do not expect the adoption of this standard to have a material impact on our consolidated financial position, results of operations or cash flows.

16.   Business Combinations

In the first six months of 2015, we completed two business combinations within our Roto-Rooter segment for $6.6 million in cash to increase our market penetration in Omaha, Nebraska and Scranton, Pennsylvania.  A substantial portion of this aggregate purchase price was allocated to goodwill.  The operating results of these business combinations have been included in our results of operations since the acquisition date and are not material for the three and six-month periods ended June 30, 2015 nor for the comparable prior year periods.

-14-

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc.  VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible.  Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families.  Roto-Rooter’s services are focused on providing plumbing, drain cleaning and other related services to both residential and commercial customers.  Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Service revenues and sales	$	381,921		$	360,182		$	758,573		$	718,482
Net income	$	26,975		$	24,363		$	51,512		$	44,937
Diluted EPS	$	1.55		$	1.36		$	2.96		$	2.48
Adjusted net income	$	29,716		$	26,580		$	56,547		$	50,293
Adjusted diluted EPS	$	1.71		$	1.50		$	3.25		$	2.81
Adjusted EBITDA	$	57,689		$	52,213		$	110,538		$	99,885
Adjusted EBITDA as a % of revenue		15.1	%		14.5	%		14.6	%		13.9	%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”) and Adjusted EBITDA are not measures derived in accordance with GAAP.  We provide non-GAAP measures to help readers evaluate our operating results, compare our operating performance with that of similar companies that have different capital structures and help evaluate our ability to meet future debt service, capital expenditure and working capital requirements.  Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP.  A reconciliation of our non-GAAP measures are presented on pages 28-30.

For the three months ended June 30, 2015, the increase in consolidated service revenues and sales was driven by a 9.7% increase at Roto-Rooter and a 4.7% increase at VITAS.  The increase in service revenues at Roto-Rooter was driven primarily by an increase in the water restoration business line as well as an increase in plumbing revenue. Water restoration is the remediation or removal of water and humidity after a flood.  The increase in service revenues at VITAS was a result of Medicare reimbursement rates increasing 1.4%, a 5.1% increase in days of care, offset by geographical and level of care mix shift.  Consolidated net income increased 10.7% due to higher revenues at both VITAS and Roto-Rooter combined with leveraging our current infrastructure resulting in operating costs growing at a slower rate than revenue.   Diluted EPS increased 14.0% as a result of the increase in net income as well as a lower number of shares outstanding.  Adjusted EBITDA as a percent of revenue increased 0.6%.   See page 31 for additional VITAS operating metrics.

For the six months ended June 30, 2015, the increase in consolidated service revenues and sales was driven by a 9.5% increase at Roto-Rooter and a 4.1% increase at VITAS.  The increase in service revenues at Roto-Rooter was driven primarily by an increase in the water restoration business line as well as an increase in plumbing revenue.  The increase in service revenues at VITAS was a result of Medicare reimbursement rates increasing 1.4%, a 4.3% increase in days of care offset by level of care and geographical mix shift.  Consolidated net income increased 14.6% due to higher revenues at both VITAS and Roto-Rooter combined with leveraging our current infrastructure resulting in operating costs growing at a slower rate than revenue.   Diluted EPS increased 19.4% as a result of the increase in net income as well as a lower number of shares outstanding.  Adjusted EBITDA as a percent of revenue increased 0.7%.   See page 31 for additional VITAS operating metrics.

VITAS expects its full-year 2015 revenue growth, prior to Medicare cap, to be in the range of 4.0% to 5.0%.  Admissions in 2015 are estimated to increase 4.0% to 5.0%.  Adjusted EBITDA margin, prior to Medicare cap, is estimated to be 14.0% to 15.0%.  Medicare cap billing limitations are estimated to be $2.8 million in 2015. Roto-Rooter expects full-year 2015 revenue growth of 5.0% to 6.0%.  The revenue estimate is a result of continued expansion in water restoration services and increased job pricing of approximately 1.0%. Adjusted EBITDA margin for 2015 is estimated in the range of 19.5% to 20.0%.  We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

-15-

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2014 to June 30, 2015 include the following:

•   An $18.6 million increase in cash due to cash generated by operations and an increase in borrowings on our revolving line of credit partially offset by treasury stock purchases, capital expenditures and cash dividends.

•   A $5.5 million decrease in accounts in accounts receivable.  See additional discussion below.

•   A $5.8 million increase in goodwill due to two acquisitions at Roto-Rooter.

•   A $7.5 million decrease in accounts payable due to timing of payments.

•   A $5.8 million decrease in income taxes due to timing of payments.

Net cash provided by operating activities increased $24.5 million primarily as a result of higher net income, payment of litigation settlements in 2014 that did not recur in 2015 and the timing of other disbursements.  Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We have issued $36.6 million in standby letters of credit as of June 30, 2015, for insurance purposes.  Issued letters of credit reduce our available credit under the revolving credit agreement.  As of June 30, 2015, we have approximately $248.4 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Significant changes in our accounts receivable balances are driven mainly by the timing of payments received from the Federal government at our VITAS subsidiary.  We typically receive a payment in excess of $35.0 million from the Federal government from hospice services every other Friday.  The timing of period end will have a significant impact on the accounts receivable at VITAS.  These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.

Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly.  We are in compliance with all financial and other debt covenants as of June 30, 2015 and anticipate remaining in compliance throughout 2015.

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas,  United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a then registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

-16-

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”).  Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action.  The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS.  The defendants filed a motion to dismiss on September 24, 2013.  The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014. 

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California, United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government partially intervened in Gonzales.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.  

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the Spottiswood,  Urick, and  Gonzales complaints with the 2013 Action.  As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes.  The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators.  The Spottiswood relator filed an action under the Illinois False Claims Act, The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014.  The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters.  In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.  In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

The costs incurred related to U.S. v. Vitas and related regulatory matters were $1.4 million and $410,000 for the quarters ended June 30, 2015 and 2014, respectively. For the six months ended June 30, 2015 and 2014, the net costs were $2.7 million and $1.2 million, respectively.

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance.  On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al., No. 13 Civ. 1854 (LPS) (D. Del.).  It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant.  Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare.  The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

-17-

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al., No. 13 Civ. 833 (MDB) (S.D. Ohio).  She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant.  Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls.  The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants.  The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole.  Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6).  On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware.  Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke.

On October 15, 2014, Plaintiff KBC filed a motion to consolidate KBC with North.  On February 2, 2015 the court granted the motion for consolidation in full, appointing Plaintiff KBC the sole lead plaintiff and its counsel, the sole lead and liaison counsel.  The court ordered that both cases will proceed under the caption In re Chemed Corp. Shareholder and Derivative Litigation, No. 13 Civ. 1854 (LPS) (CJB) (D. Del.).  Plaintiff KBC has designated its pending complaint as the operative complaint in the consolidated proceedings.  Defendants have renewed their motion to dismiss the claims and allegations.

The Company intends to defend vigorously against the allegations in each of the above lawsuits.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity.  Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

Results of Operations

Three months ended June 30, 2015 versus 2014 - Consolidated Results

Our service revenues and sales for the second quarter of 2015 increased 6.0% versus services and sales revenues for the second quarter of 2014.  Of this increase, $12.4 million was attributable to VITAS and a $9.3 million increase was attributable to Roto-Rooter.  The following chart shows the components of those changes (in thousands):

	Increase/(Decrease)
	Amount		Percent
VITAS
Routine homecare	$	12,956	6.5
Continuous care		(131)	(0.3)
General inpatient		(534)	(2.1)
Medicare cap		143	100.0
Roto-Rooter
Plumbing		3,531	8.2
Drain cleaning		(295)	(0.8)
Water restoration		5,756	169.3
Contractor operations		337	3.7
Other		(24)	(0.5)
Total	$	21,739	6.0

-18-

The increase in VITAS’ revenues for the second quarter of 2015 versus the second quarter of 2014 was a combination of Medicare reimbursement rates increasing approximately 1.4% and a 5.1% increase in days of care offset by level of care and geographical mix shift.

Days of care during the quarter ended June 30 were as follows:

	Days of Care
	2015		2014		Percent
Routine homecare		1,300,479		1,231,741		5.6
Continuous care		51,250		51,647		(0.8	)
General inpatient		39,006		39,430		(1.1	)
Total days of care		1,390,735		1,322,818		5.1

Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the second quarter of 2015 versus 2014 is attributable to a 5.1% increase in job count and a 3.1% increase in a combination of price and service mix shift.  Drain cleaning revenues for the second quarter of 2015 versus 2014 reflect a 4.4% decrease in the number of jobs performed, offset by a 3.6% increase in a combination of price and service mix shift.  Water restoration increased 169.3% as a result of continued expansion into other Roto-Rooter locations.  Contractor operations increased 3.7% and Other Roto-Rooter revenue decreased 0.5%.

The consolidated gross margin was 29.1% in the second quarter of 2015 as compared with 28.6% in the second quarter of 2014.  On a segment basis, VITAS’ gross margin was 21.9% in the second quarter of 2015, essentially flat when compared to the second quarter of 2014.  The Roto-Rooter segment’s gross margin was 48.0% for the second quarter of 2015 as compared with 46.8% for the second quarter of 2014.  The gross margin increase was mainly the result of favorable health insurance experience during the second quarter of 2015.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

	Three months ended June 30,
	2015		2014
SG&A expenses before the impact of market gains of deferred compensation plans,
long-term incentive compensation, and OIG investigation expenses	$	54,627	$	51,976
Long-term incentive compensation		1,457		613
Expenses related to OIG investigation		1,412		410
Market value gains related to assets held in deferred compensation trusts		498		650
Total SG&A expenses	$	57,994	$	53,649

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the second quarter of 2015 were up 5.1% when compared to the second quarter of 2014.  The increase was mainly a result of the increase in variable expenses caused by increased revenue as well as normal salary increases and higher bad debt expense in 2015.

-19-

Other income - net comprise (in thousands):

	Three months ended June 30,
	2015			2014
Market value gains on assets held in deferred
compensation trusts	$	498		$	650
Loss on disposal of property and equipment		(63	)		(48	)
Interest income - net		86			58
Other		15			96
Total other income - net	$	536		$	756

Our effective income tax rate was 38.9% in the second quarter of 2015 essentially equal to the second quarter of 2014.

Net income for both periods included the following after-tax items/adjustments that reduced or increased after-tax earnings (in thousands):

	Three months ended June 30,
	2015			2014
VITAS
Expenses related to OIG investigation	$	(868	)	$	(254	)
Roto-Rooter
Acquisition expenses		(80	)		-
Expenses related to litigation settlements		-			(20	)
Corporate
Stock option expense		(849	)		(722	)
Noncash impact of change in accounting for convertible debt		-			(714	)
Long-term incentive compensation		(921	)		(388	)
Expenses related to securities litigation		(23	)		(119	)
Total	$	(2,741	)	$	(2,217	)

Three months ended June 30, 2015 versus 2014 - Segment Results

The change in after-tax earnings for the second quarter of 2015 versus the second quarter of 2014 is due to (in thousands):

	Increase/(Decrease)
	Amount		Percent
VITAS	$	908		4.3
Roto-Rooter		1,434		13.4
Corporate		270		3.7
	$	2,612		10.7

VITAS’ after-tax earnings were positively impacted in 2015 compared to 2014 by a $12.4 million increase in revenue.   After-tax earnings as a percent of revenue in 2015 were 7.9%, essentially equal to the second quarter of 2014.

Roto-Rooter’s after-tax earnings were positively impacted in 2015 compared to 2014 primarily by a $5.8 million revenue increase in Roto-Rooter’s water restoration line of business and a $3.5 million increase in plumbing revenue.  After-tax earnings as a percent of revenue at Roto-Rooter in 2015 were 11.5% as compared to 11.1% in 2014.  This increase is largely the result of higher sales and gross profit in 2015, partially offset by higher SG&A expenses.  Favorable health insurance experience during the second quarter of 2015 contributed to the higher gross profit.

-20-

Results of Operations

Six months ended June 30, 2015 versus 2014 - Consolidated Results

Our service revenues and sales for the first six months of 2015 increased 5.6% versus services and sales revenues for the first six months of 2014.  Of this increase, $21.6 million was attributable to VITAS and an $18.5 million increase was attributable to Roto-Rooter.  The following chart shows the components of those changes (in thousands):

	Increase/(Decrease)
	Amount		Percent
VITAS
Routine homecare	$	22,100	5.6
Continuous care		(115)	(0.2)
General inpatient		189	0.4
Medicare cap		(539)	(76.6)
Roto-Rooter
Plumbing		4,525	5.1
Drain cleaning		(1,304)	(1.8)
Water restoration		14,695	298.6
Contractor operations		778	4.3
Other		(238)	(2.3)
Total	$	40,091	5.6

The increase in VITAS’ revenues for the first six months of 2015 versus the first six months of 2014 was a combination of Medicare reimbursement rates increasing approximately 1.4% and a 4.3% increase in days of care offset by level of care and geographical mix shift.  In the first six months of 2015, VITAS recorded a positive revenue adjustment of $165,000 related to one program’s Medicare cap liability recorded in the fourth quarter of 2014. This compares to a positive revenue adjustment of $704,000 recorded in the first six months of 2014.

Days of care for the six months ended June 30 were as follows:

	Days of Care
	2015		2014		Percent
Routine homecare		2,542,212		2,429,079		4.7
Continuous care		104,090		103,477		0.6
General inpatient		78,579		78,758		(0.2	)
Total days of care		2,724,881		2,611,314		4.3

Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first six months of 2015 versus 2014 is attributable to a 1.5% decrease in job count, offset by a 6.6% increase in a combination of price and service mix shift.  Drain cleaning revenues for the first six months of 2015 versus 2014 reflect a 5.3% decrease in the number of jobs performed, offset by a 3.5% increase in a combination of price and service mix shift.  Water restoration increased 298.6% as a result of continued expansion into other Roto-Rooter locations.  Water restoration is the remediation or removal of water and humidity after a flood. Contractor operations increased 4.3% and Other Roto-Rooter revenue decreased 2.3%.

The consolidated gross margin was 28.9% in the first six months of 2015 as compared with 28.3% in the first six months of 2014.  On a segment basis, VITAS’ gross margin was 21.6% in the first six months of 2015 essentially equal to the first six months of 2014.  The Roto-Rooter segment’s gross margin was 47.6% for the first six months of 2015 as compared with 46.6% for the first six months of 2014.  The gross margin increase was mainly the result of favorable health and casualty insurance experience during the first six months of 2015.

-21-

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

	Six months ended June 30,
	2015		2014
SG&A expenses before the impact of market gains of deferred compensation
plans, long-term incentive compensation, and OIG investigation expenses	$	110,057	$	105,364
Long-term incentive compensation		2,391		986
Expenses related to OIG investigation		2,686		1,158
Market value gains related to assets held in
deferred compensation trusts		1,448		1,812
Total SG&A expenses	$	116,582	$	109,320

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the first six months of 2015 were up 4.5% when compared to the first six months of 2014.  The increase was mainly a result of the increase in variable expenses caused by increased revenue as well as normal salary increases and higher bad debt expenses in 2015.

Other income - net comprise (in thousands)

	Six months ended June 30,
	2015			2014
Market value gains on assets held in deferred
compensation trusts	$	1,448		$	1,812
Loss on disposal of property and equipment		(15	)		(326	)
Interest income - net		130			8
Other		(464	)		78
Total other income - net	$	1,099		$	1,572

Our effective income tax rate was 38.9% in the first six months of 2015, essentially equal to the first six months of 2014.

Net income for both periods included the following after-tax items/adjustments to after-tax earnings (in thousands):

	Six Months Ended June 30,
	2015			2014
VITAS
Legal expenses of OIG investigation	$	(1,658	)	$	(718	)
Expenses related to litigation settlements		-			(70	)
Acquisition expenses		-			(1	)
Roto-Rooter
Expenses related to litigation settlements		(3	)		(137	)
Acquisition expenses		(80	)		-
Corporate
Stock option expense		(1,759	)		(1,544	)
Noncash impact of change in accounting for convertible debt		-			(2,143	)
Long-term incentive compensation		(1,512	)		(624	)
Expenses of securities litigation		(23	)		(119	)
Total	$	(5,035	)	$	(5,356	)

-22-

Six months ended June 30, 2015 versus 2014 - Segment Results

The change in after-tax earnings for the first six months of 2015 versus the first six months of 2014 is due to (in thousands):

	Increase/(Decrease)
	Amount		Percent
VITAS	$	2,065		5.3
Roto-Rooter		3,410		16.4
Corporate		1,100		7.4
	$	6,575		14.6

VITAS’ after-tax earnings were positively impacted in 2015 compared to 2014 by a $21.6 million increase in revenue.   After-tax earnings as a percent of revenue in 2015 were 7.5% as compared to 7.4% in 2014.

Roto-Rooter’s after-tax earnings were positively impacted in 2015 compared to 2014 primarily by a $14.7 million revenue increase in Roto-Rooter’s water restoration line of business and a $4.5 million increase in plumbing revenue.  After-tax earnings as a percent of revenue at Roto-Rooter in 2015 were 11.4% as compared to 10.7% in 2014.  This increase is largely the result of higher sales and gross profit in 2015, partially offset by higher SG&A expenses.  Favorable casualty and health insurance experience during 2015 contributed to the higher gross profit.

-23-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE THREE MONTHS ENDED JUNE 30, 2015
(in thousands)(unaudited)
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
2015 (a)
Service revenues and sales	$	276,460		$	105,461		$	-		$	381,921
Cost of services provided and goods sold		215,778			54,885			-			270,663
Selling, general and administrative expenses		22,237			28,241			7,516			57,994
Depreciation		4,724			3,205			153			8,082
Amortization		171			128			283			582
Total costs and expenses		242,910			86,459			7,952			337,321
Income/(loss) from operations		33,550			19,002			(7,952	)		44,600
Interest expense		(53	)		(98	)		(818	)		(969	)
Intercompany interest income/(expense)		1,755			805			(2,560	)		-
Other income/(expense)—net		49			(12	)		499			536
Income/(expense) before income taxes		35,301			19,697			(10,831	)		44,167
Income taxes		(13,501	)		(7,544	)		3,853			(17,192	)
Net income/(loss)	$	21,800		$	12,153		$	(6,978	)	$	26,975
(a) The following amounts are included in net income (in thousands):
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(1,343	)	$	(1,343	)
Long-term incentive compensation		-			-			(1,457	)		(1,457	)
Expenses related to securities litigation		-			-			(37	)		(37	)
Acquisition expenses		-			(131	)		-			(131	)
Expenses related to OIG investigation		(1,412	)		-			-			(1,412	)
Total	$	(1,412	)	$	(131	)	$	(2,837	)	$	(4,380	)
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(849	)	$	(849	)
Long-term incentive compensation		-			-			(921	)		(921	)
Expenses related to securities litigation		-			-			(23	)		(23	)
Acquisition expenses		-			(80	)		-			(80	)
Expenses related to OIG investigation		(868	)		-			-			(868	)
Total	$	(868	)	$	(80	)	$	(1,793	)	$	(2,741	)

-24-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE THREE MONTHS ENDED JUNE 30, 2014
(in thousands)(unaudited)
	VITAS			Roto-Rooter			Corporate			Chemed Consolidated
2014 (a)
Service revenues and sales	$	264,026		$	96,156		$	-		$	360,182
Cost of services provided and goods sold		205,818			51,189			-			257,007
Selling, general and administrative expenses		21,002			25,705			6,942			53,649
Depreciation		4,564			2,561			147			7,272
Amortization		205			137			393			735
Total costs and expenses		231,589			79,592			7,482			318,663
Income/(loss) from operations		32,437			16,564			(7,482	)		41,519
Interest expense		(57	)		(111	)		(2,261	)		(2,429	)
Intercompany interest income/(expense)		1,517			680			(2,197	)		-
Other income/(expense)—net		(95	)		198			653			756
Income/(expense) before income taxes		33,802			17,331			(11,287	)		39,846
Income taxes		(12,910	)		(6,612	)		4,039			(15,483	)
Net income/(loss)	$	20,892		$	10,719		$	(7,248	)	$	24,363
(a) The following amounts are included in net income (in thousands):
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(1,144	)	$	(1,144	)
Noncash impact of accounting for convertible debt		-			-			(1,130	)		(1,130	)
Long-term incentive compensation		-			-			(613	)		(613	)
Expenses related to litigation settlements		-			(32	)		-			(32	)
Expenses related to securities litigation		-			-			(189	)		(189	)
Expenses related to OIG investigation		(410	)		-			-			(410	)
Total	$	(410	)	$	(32	)	$	(3,076	)	$	(3,518	)
		VITAS			Roto-Rooter			Corporate			Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(722	)	$	(722	)
Noncash impact of accounting for convertible debt		-			-			(714	)		(714	)
Long-term incentive compensation		-			-			(388	)		(388	)
Expenses related to litigation settlements		-			(20	)		-			(20	)
Expenses related to securities litigation		-			-			(119	)		(119	)
Expenses related to OIG investigation		(254	)		-			-			(254	)
Total	$	(254	)	$	(20	)	$	(1,943	)	$	(2,217	)

-25-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE SIX MONTHS ENDED JUNE 30, 2015
(in thousands)(unaudited)
										Chemed
	VITAS			Roto-Rooter			Corporate			Consolidated
2015 (a)
Service revenues and sales	$	546,073		$	212,500		$	-		$	758,573
Cost of services provided and goods sold		428,274			111,274			-			539,548
Selling, general and administrative expenses		44,207			57,002			15,373			116,582
Depreciation		9,509			6,299			306			16,114
Amortization		338			236			584			1,158
Total costs and expenses		482,328			174,811			16,263			673,402
Income/(loss) from operations		63,745			37,689			(16,263	)		85,171
Interest expense		(110	)		(194	)		(1,634	)		(1,938	)
Intercompany interest income/(expense)		3,482			1,642			(5,124	)		-
Other income/(expense)—net		(384	)		35			1,448			1,099
Income/(expense) before income taxes		66,733			39,172			(21,573	)		84,332
Income taxes		(25,617	)		(15,011	)		7,808			(32,820	)
Net income/(loss)	$	41,116		$	24,161		$	(13,765	)	$	51,512
(a) The following amounts are included in net income (in thousands):
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(2,787	)	$	(2,787	)
Long-term incentive compensation		-			-			(2,391	)		(2,391	)
Expenses related to litigation settlements		-			(5	)		-			(5	)
Expenses related to securities litigation		-			-			(37	)		(37	)
Acquisition expenses		-			(131	)		-			(131	)
Expenses related to OIG investigation		(2,686	)		-			-			(2,686	)
Total	$	(2,686	)	$	(136	)	$	(5,215	)	$	(8,037	)
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(1,759	)	$	(1,759	)
Long-term incentive compensation		-			-			(1,512	)		(1,512	)
Expenses related to litigation settlements		-			(3	)		-			(3	)
Expenses related to securities litigation		-			-			(23	)		(23	)
Acquisition expenses		-			(80	)		-			(80	)
Expenses related to OIG investigation		(1,658	)		-			-			(1,658	)
Total	$	(1,658	)	$	(83	)	$	(3,294	)	$	(5,035	)

-26-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE SIX MONTHS ENDED JUNE 30, 2014
(in thousands)(unaudited)
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
2014 (a)
Service revenues and sales	$	524,438		$	194,044		$	-		$	718,482
Cost of services provided and goods sold		411,210			103,616			-			514,826
Selling, general and administrative expenses		42,716			52,887			13,717			109,320
Depreciation		9,178			4,961			282			14,421
Amortization		624			282			838			1,744
Total costs and expenses		463,728			161,746			14,837			640,311
Income/(loss) from operations		60,710			32,298			(14,837	)		78,171
Interest expense		(112	)		(208	)		(5,924	)		(6,244	)
Intercompany interest income/(expense)		2,860			1,330			(4,190	)		-
Other income/(expense)—net		(388	)		139			1,821			1,572
Income/(expense) before income taxes		63,070			33,559			(23,130	)		73,499
Income taxes		(24,019	)		(12,808	)		8,265			(28,562	)
Net income/(loss)	$	39,051		$	20,751		$	(14,865	)	$	44,937
(a) The following amounts are included in net income (in thousands):
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(2,453	)	$	(2,453	)
Noncash impact of accounting for convertible debt		-			-			(3,389	)		(3,389	)
Long-term incentive compensation		-			-			(986	)		(986	)
Expenses related to litigation settlements		(113	)		(225	)		-			(338	)
Expenses related to securities litigation		-			-			(189	)		(189	)
Acquisition expenses		(1	)		-			-			(1	)
Expenses related to OIG investigation		(1,158	)		-			-			(1,158	)
Total	$	(1,272	)	$	(225	)	$	(7,017	)	$	(8,514	)
											Chemed
		VITAS			Roto-Rooter			Corporate			Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(1,544	)	$	(1,544	)
Noncash impact of accounting for convertible debt		-			-			(2,143	)		(2,143	)
Long-term incentive compensation		-			-			(624	)		(624	)
Expenses related to litigation settlements		(70	)		(137	)		-			(207	)
Expenses related to securities litigation		-			-			(119	)		(119	)
Acquisition expenses		(1	)		-			-			(1	)
Expenses related to OIG investigation		(718	)		-			-			(718	)
Total	$	(789	)	$	(137	)	$	(4,430	)	$	(5,356	)

-27-

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA
Chemed Corporation and Subsidiary Companies
(in thousands)													Chemed
For the three months ended June 30, 2015	VITAS				Roto-Rooter				Corporate				Consolidated
Net income/(loss)		$	21,800			$	12,153			$	(6,978	)		$	26,975
Add/(deduct):
Interest expense			53				98				818				969
Income taxes			13,501				7,544				(3,853	)			17,192
Depreciation			4,724				3,205				153				8,082
Amortization			171				128				283				582
EBITDA			40,249				23,128				(9,577	)			53,800
Add/(deduct):
Intercompany interest expense/(income)			(1,755	)			(805	)			2,560				-
Interest income			(78	)			(9	)			1				(86	)
Expenses related to OIG investigation			1,412				-				-				1,412
Acquisition expenses			-				131				-				131
Expenses related to securities litigation			-				-				37				37
Advertising cost adjustment			-				(405	)			-				(405	)
Stock option expense			-				-				1,343				1,343
Long-term incentive compensation			-				-				1,457				1,457
Adjusted EBITDA		$	39,828			$	22,040			$	(4,179	)		$	57,689
													Chemed
For the three months ended June 30, 2014	VITAS				Roto-Rooter				Corporate				Consolidated
Net income/(loss)		$	20,892			$	10,719			$	(7,248	)		$	24,363
Add/(deduct):
Interest expense			57				111				2,261				2,429
Income taxes			12,910				6,612				(4,039	)			15,483
Depreciation			4,564				2,561				147				7,272
Amortization			205				137				393				735
EBITDA			38,628				20,140				(8,486	)			50,282
Add/(deduct):
Intercompany interest expense/(income)			(1,517	)			(680	)			2,197				-
Interest income			(43	)			(12	)			(3	)			(58	)
Expenses related to OIG investigation			410				-				-				410
Advertising cost adjustment			-				(399	)			-				(399	)
Expenses related to litigation settlements			-				32				-				32
Long-term incentive compensation			-				-				613				613
Stock option expense			-				-				1,144				1,144
Expenses related to securities litigation			-				-				189				189
Adjusted EBITDA		$	37,478			$	19,081			$	(4,346	)		$	52,213

-28-

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA
Chemed Corporation and Subsidiary Companies
(in thousands)													Chemed
For the six months ended June 30, 2015	VITAS				Roto-Rooter				Corporate				Consolidated
Net income/(loss)		$	41,116			$	24,161			$	(13,765	)		$	51,512
Add/(deduct):
Interest expense			110				194				1,634				1,938
Income taxes			25,617				15,011				(7,808	)			32,820
Depreciation			9,509				6,299				306				16,114
Amortization			338				236				584				1,158
EBITDA			76,690				45,901				(19,049	)			103,542
Add/(deduct):
Intercompany interest expense/(income)			(3,482	)			(1,642	)			5,124				-
Interest income			(110	)			(20	)			-				(130	)
Expenses related to OIG investigation			2,686				-				-				2,686
Acquisition expenses			-				131				-				131
Expenses related to litigation settlements			-				5				-				5
Advertising cost adjustment			-				(911	)			-				(911	)
Stock option expense			-				-				2,787				2,787
Long-term incentive compensation			-				-				2,391				2,391
Expenses related to securities litigation			-				-				37				37
Adjusted EBITDA		$	75,784			$	43,464			$	(8,710	)		$	110,538
													Chemed
For the six months ended June 30, 2014	VITAS				Roto-Rooter				Corporate				Consolidated
Net income/(loss)		$	39,051			$	20,751			$	(14,865	)		$	44,937
Add/(deduct):
Interest expense			112				208				5,924				6,244
Income taxes			24,019				12,808				(8,265	)			28,562
Depreciation			9,178				4,961				282				14,421
Amortization			624				282				838				1,744
EBITDA			72,984				39,010				(16,086	)			95,908
Add/(deduct):
Intercompany interest expense/(income)			(2,860	)			(1,330	)			4,190				-
Interest income			20				(19	)			(9	)			(8	)
Expenses related to OIG investigation			1,158				-				-				1,158
Acquisition expenses			1				-				-				1
Advertising cost adjustment			-				(1,140	)			-				(1,140	)
Expenses related to litigation settlements			113				225				-				338
Long-term incentive compensation			-				-				986				986
Stock option expense			-				-				2,453				2,453
Expenses related to securities litigation			-				-				189				189
Adjusted EBITDA		$	71,416			$	36,746			$	(8,277	)		$	99,885

-29-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Net income as reported	$	26,975	$	24,363	$	51,512	$	44,937
Add/(deduct) after-tax cost of:
Stock option expense		849		722		1,759		1,544
Expenses of OIG investigation		868		254		1,658		718
Long-term incentive compensation		921		388		1,512		624
Expenses related to litigation settlements		-		20		3		207
Expenses related to securities settlements		23		119		23		119
Additional interest expense resulting from the change in accounting
for the conversion feature of the convertible notes		-		714		-		2,143
Acquisition expenses		80		-		80		1
Adjusted net income	$	29,716	$	26,580	$	56,547	$	50,293
Diluted Earnings Per Share As Reported
Net income	$	1.55	$	1.36	$	2.96	$	2.48
Average number of shares outstanding		17,419		17,880		17,419		18,097
Adjusted Diluted Earnings Per Share
Adjusted net income	$	1.71	$	1.50	$	3.25	$	2.81
Adjusted average number of shares outstanding*		17,419		17,759		17,419		17,895
* Adjusted diluted average shares outstanding excludes the estimated dilutive impact of the Convertible Notes prior to conversion of these Notes on May 15, 2014 (121,000 shares for the three months ended June 30, 2014 and 202,000 shares for the six months ended June 30, 2014) as this impact was entirely offset upon the exercise of the note hedges on May 15, 2014.

-30-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
	Three Months Ended June 30,						Six Months Ended June 30,
OPERATING STATISTICS	2015			2014			2015			2014
Net revenue ($000)
Homecare	$	213,374		$	200,418		$	417,915		$	395,815
Inpatient		25,498			26,032			52,214			52,025
Continuous care		37,588			37,719			75,779			75,894
Total before Medicare cap allowance	$	276,460		$	264,169		$	545,908		$	523,734
Medicare cap allowance		-			(143)			165			704
Total	$	276,460		$	264,026		$	546,073		$	524,438
Net revenue as a percent of total before Medicare cap allowances
Homecare		77.2	%		75.9	%		76.5	%		75.6	%
Inpatient		9.2			9.8			9.6			9.9
Continuous care		13.6			14.3			13.9			14.5
Total before Medicare cap allowance		100.0			100.0			100.0			100.0
Medicare cap allowance		-			(0.1)			-			0.1
Total		100.0	%		99.9	%		100.0	%		100.1	%
Average daily census (days)
Homecare		11,285			10,546			11,082			10,511
Nursing home		3,006			2,989			2,964			2,909
Routine homecare		14,291			13,535			14,046			13,420
Inpatient		429			433			434			435
Continuous care		563			568			575			572
Total		15,283			14,536			15,055			14,427
Total Admissions		16,683			15,771			33,951			32,124
Total Discharges		15,912			15,673			33,019			31,678
Average length of stay (days)		78.5			82.4			79.1			81.7
Median length of stay (days)		15.0			16.0			14.0			15.0
ADC by major diagnosis
Cerebro		28.6	%		6.3	%		28.4	%		6.4	%
Neurological		23.0			41.2			23.4			40.9
Cancer		16.8			17.3			16.9			17.4
Cardio		17.4			15.7			17.5			15.4
Respiratory		8.0			7.7			7.9			7.8
Other		6.2			11.8			5.9			12.1
Total		100.0	%		100.0	%		100.0	%		100.0	%
Admissions by major diagnosis
Cerebro		18.9			7.7	%		18.8	%		7.3	%
Neurological		11.7			21.6			12.3			22.0
Cancer		32.5			33.4			31.5			33.1
Cardio		15.6			15.3			15.7			14.6
Respiratory		10.0			9.6			10.4			9.8
Other		11.3			12.4			11.3			13.2
Total		100.0	%		100.0	%		100.0	%		100.0	%
Direct patient care margins
Routine homecare		52.4	%		53.4	%		52.6	%		53.2	%
Inpatient		6.0			6.9			7.2			5.6
Continuous care		16.7			17.5			16.3			17.0
Homecare margin drivers (dollars per patient day)
Labor costs	$	56.38		$	53.89		$	56.79		$	54.65
Drug costs		6.94			7.26			6.73			7.25
Home medical equipment		6.57			6.76			5.90			6.69
Medical supplies		3.06			3.17			2.99			3.20
Inpatient margin drivers (dollars per patient day)
Labor costs	$	348.40		$	337.30		$	343.85		$	343.50
Continuous care margin drivers (dollars per patient day)
Labor costs	$	589.84		$	581.00		$	588.72		$	587.40
Bad debt expense as a percent of revenues		1.0	%		1.0	%		1.0	%		1.0	%
Accounts receivable -- Days of revenue outstanding- excluding unapplied Medicare payments		40.8			36.6		n.a			n.a
Accounts receivable -- Days of revenue outstanding- including unapplied Medicare payments		31.0			24.4		n.a			n.a

-31-

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made.  These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements.  Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends.  In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters.  Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved.  Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

Item 3.  Quantitative and Qualitative Disclosures about Market Risk

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit.  At June 30, 2015, the Company had $160.0 million of variable rate debt outstanding.  For each $10 million dollars borrowed under the credit facility, an increase or decrease of 100 basis points (1% point), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Item 4.  Controls and Procedures

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.  Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.  There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.  Legal Proceedings

For information regarding the Company’s legal proceedings, see note 10, Legal and Regulatory Matters, under Part I, Item I of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

-32-

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds

Item 2(c). Purchases of Equity Securities by Issuer and Affiliated Purchasers

The following table shows the activity related to our share repurchase program for the first six months of 2015:

	Total Number		Weighted		Cumulative Shares		Dollar Amount
	of Shares		Price Paid Per		Repurchased Under		Remaining Under
	Repurchased		Share		the Program		The Program
February 2011 Program
January 1 through January 31, 2015		-	$	-		6,074,819	$	11,808,785
February 1 through February 28, 2015		-		-		6,074,819		11,808,785
March 1 through March 31, 2015		-		-		6,074,819	$	111,808,785
First Quarter Total		-	$	-
April 1 through April 30, 2015		31,239	$	116.66		6,106,058	$	108,163,534
May 31 through May 31, 2015		218,761		119.38		6,324,819		82,047,193
June 1 through June 30, 2015		-		-		6,324,819	$	82,047,193
Second Quarter Total		250,000	$	119.05
On March 13, 2015 our Board of Directors authorized an additional $100 million under the February 2011 Repurchase
Program.

Item 3.    Defaults Upon Senior Securities

None

Item 4.    Mine Safety Disclosures

None

Item 5.    Other Information

None

-33-

Item 6.    Exhibits

Exhibit No.	Description
31.1	Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
31.2	Certification by David P. Williams pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange  Act of 1934.
31.3	Certification by Arthur V. Tucker, Jr. pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
32.1	Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification by David P. Williams pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.3	Certification by Arthur V. Tucker, Jr. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Chemed Corporation
			(Registrant)
Dated:	July 31, 2015	By:	/s/ Kevin J. McNamara
			Kevin J. McNamara
			(President and Chief Executive Officer)
Dated:	July 31, 2015	By:	/s/ David P. Williams
			David P. Williams
			(Executive Vice President and Chief Financial Officer)
Dated:	July 31, 2015	By:	/s/ Arthur V. Tucker, Jr.
			Arthur V. Tucker, Jr.
			(Vice President and Controller)

-34-

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, Kevin J. McNamara, certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter  (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.   The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function:

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	July 31, 2015	/s/ Kevin J. McNamara
		Kevin J. McNamara
		(President and Chief
		Executive Officer)

E-1

EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, David P. Williams, certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function:

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	July 31, 2015	/s/ David P. Williams
		David P. Williams
		(Executive Vice President and Chief Financial
		Officer)

E-2

EX-31.3

EXHIBIT 31.3

CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, Arthur V. Tucker, Jr., certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,

c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function:

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	July 31, 2015	/s/ Arthur V. Tucker, Jr.
		Arthur V. Tucker, Jr.
		(Vice President and
		Controller)

E-3

EX-32.1

EXHIBIT 32.1

CERTIFICATION BY KEVIN J. MCNAMARA

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as President and Chief Executive Officer of Chemed Corporation (“Company”), does hereby certify that:

1) the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2015 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:	July 31, 2015	/s/ Kevin J. McNamara
		Kevin J. McNamara
		(President and Chief
		Executive Officer)

E-4

EX-32.2

EXHIBIT 32.2

CERTIFICATION BY DAVID P. WILLIAMS

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Executive Vice President and Chief Financial Officer of Chemed Corporation (“Company”), does hereby certify that:

1) the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2015 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:	July 31, 2015	/s/ David P. Williams
		David P. Williams
		(Executive Vice President and Chief Financial
		Officer)

E-5

EX-32.3

EXHIBIT 32.3

CERTIFICATION BY ARTHUR V. TUCKER, JR.

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Vice President and Controller of Chemed Corporation (“Company”), does hereby certify that:

1) the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2015 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:	July 31, 2015	/s/ Arthur V. Tucker, Jr.
		Arthur V. Tucker, Jr.
		(Vice President and
		Controller)

E-6

XML

Long-Term Debt (Schedule of Principal Payments of the Term Loan) (Details) $ in Thousands	Jun. 30, 2015 USD ($)
Debt Instrument [Line Items]
Total	$ 160,000
Medium-term Notes [Member]
Debt Instrument [Line Items]
2015	3,750
2016	7,500
2017	8,750
2018	10,000
2019	65,000
Total	$ 95,000

XML

Cash Overdrafts And Cash Equivalents (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Cash Overdrafts And Cash Equivalents [Abstract]
Cash overdrafts included in accounts payable	$ 3,700,000	$ 10,500,000
Cash equivalents	$ 66,000	$ 80,000
Cash equivalents weighted average rate of return	0.08%	0.06%

XML

Legal And Regulatory Matters (Details) - U.S. v. VITAS [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) item employee	Jun. 30, 2014 USD ($)
Loss Contingencies [Line Items]
Number of Patients | item			117
Current and former employees			10
Net (costs) credit incurred | $	$ 1,400,000	$ 410,000	$ 2,700,000	$ 1,200,000

XML

Revenue Recognition (Schedule Of Cost Of Charity Care) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue Recognition [Abstract]
Charity care cost	$ 1,885	$ 1,931	$ 3,859	$ 3,630

XML

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2015

Long-Term Debt [Abstract]

Debt Outstanding

Revolver	$	65,000
Term loan		95,000
Total		160,000
Current portion of term and revolving loan		(7,500)
Long-term debt	$	152,500

Schedule of Principal Payments of the Term Loan

2015	$	3,750
2016		7,500
2017		8,750
2018		10,000
2019		65,000
	$	95,000

Financial Debt Covenants

Description	Requirement
Leverage Ratio (Consolidated Indebtedness/Consolidated  Adj. EBITDA)	<  3.50 to 1.00
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges)	>  1.50 to 1.00
Annual Operating Lease Commitment	<  $50.0 million

XML

Capital Stock Repurchase Plan Transactions (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Capital Stock Repurchases Plan Transactions [Abstract]
Stock repurchase program, amount authorized	$ 100.0		$ 100.0
Shares repurchased	250,000	300,000	250,000	682,934
Weighted average price per share	$ 119.05	$ 85.04	$ 119.05	$ 85.65
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 82.0		$ 82.0

XML

Stock-Based Compensation Plans (Narrative) (Details) - USD ($) $ in Thousands			6 Months Ended
	May. 18, 2015	Feb. 20, 2015	Jun. 30, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vesting period, years			3 years
Stock Awards Granted	32,550
Cumulative compensation expense	$ 4,000
Forfeitures	$ 0
Performance Based TSR [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vesting period, years			3 years
Stock Awards Granted		10,761
Cumulative compensation expense		$ 1,500
Performance Based EPS [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vesting period, years			3 years
Stock Awards Granted		10,761
Cumulative compensation expense		$ 1,600

XML

Long-Term Debt (Narrative) (Details) - Jun. 30, 2015 - USD ($)	Total
Debt Instrument [Line Items]
Standby letters of credit issued	$ 36,600,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Unused lines of credit	$ 248,400,000
2014 Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument term	5 years
2014 Credit Agreement [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable interest rate	1.13%
2014 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Face amount of debt	$ 350,000,000
2014 Credit Agreement [Member] | Medium-term Notes [Member]
Debt Instrument [Line Items]
Face amount of debt	$ 100,000,000

XML

Concentration Of Risk (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Concentration Risk [Line Items]
Period of renewal of pharmacy services agreements			3 years
Number of days prior written notice to cancel agreements			30 days
Segment VITAS [Member]
Concentration Risk [Line Items]
VITAS made purchases from OCR	$ 9.5	$ 8.8	$ 18.7	$ 17.7
Pharmacy Services [Member] | Segment VITAS [Member]
Concentration Risk [Line Items]
Percentage of concentration risk services represent from vendor	90.00%	90.00%	90.00%	90.00%

XML

Earnings Per Share

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share

4.  Earnings per Share

Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding.  Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):

			Net Income
For the Three Months Ended June 30,		Income		Shares	Earnings per Share
2015
	Earnings	$	26,975	16,880	$	1.60
	Dilutive stock options		-	390
	Nonvested stock awards		-	149
	Diluted earnings	$	26,975	17,419	$	1.55
2014
	Earnings	$	24,363	17,236	$	1.41
	Dilutive stock options		-	376
	Nonvested stock awards		-	147
	Conversion of notes		-	121
	Diluted earnings	$	24,363	17,880	$	1.36

			Net Income
For the Six Months Ended June 30,		Income		Shares	Earnings per Share
2015
	Earnings	$	51,512	16,872	$	3.05
	Dilutive stock options		-	395
	Nonvested stock awards		-	152
	Diluted earnings	$	51,512	17,419	$	2.96
2014
	Earnings	$	44,937	17,374	$	2.59
	Dilutive stock options		-	374
	Nonvested stock awards		-	147
	Conversion of Notes		-	202
	Diluted earnings	$	44,937	18,097	$	2.48

For the three and six-month period ended June 30, 2015, 411,000 stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.  For the three and six-month period ended June 30, 2014 no stock options were so excluded.

For the three and six-months of 2014 diluted earnings per share was impacted by the issuance of 249,000 shares of capital stock under the conversion feature of our 1.875% Senior Convertible Notes (the “Notes”) on the May 15, 2014 maturity date.  Assuming these shares were issued April 1, 2014 increases average diluted shares outstanding for the second quarter of 2014 by 121,000 shares.  Similarly, the dilutive impact of this conversion feature for the first six months of 2014 was 202,000. 

XML

Independent Contractor Operations (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2015 USD ($) item	Dec. 31, 2014 USD ($)
Independent Contractor Operations [Line Items]
Notes receivable from independent contractors | $	$ 1.6	$ 1.6
Settlements of Roto-Rooter segment [Member]
Independent Contractor Operations [Line Items]
Independent contractors with sublicenses	69
Maximum [Member]
Independent Contractor Operations [Line Items]
Interest rates on loans	7.00%
Terms of the loans to independent contractors, years	5 years
Minimum [Member]
Independent Contractor Operations [Line Items]
Interest rates on loans	0.00%
Terms of the loans to independent contractors, years	2 months

XML

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2015

Financial Instruments [Abstract]

Carrying Value, Fair Value And Hierarchy Of Financial Instruments

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of          

June 30, 2015 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	51,940	$	51,940	$	-	$	-
Long-term debt		160,000		-		160,000		-

For the mutual fund investments carrying value is fair value.  All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of      December 31, 2014 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	49,147	$	49,147	$	-	$	-
Long-term debt		147,500		-		147,500		-

XML

Retirement Plans (Tables)

6 Months Ended

Jun. 30, 2015

Retirement Plans [Abstract]

Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans

Three months ended June 30,				Six months ended June 30,
2015		2014		2015		2014
$	2,991	$	3,324	$	7,178	$	7,222

XML

Independent Contractor Operations (Schedule Of Independent Contractors) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Independent Contractor Operations [Abstract]
Revenues	$ 9,527	$ 9,190	$ 18,991	$ 18,213
Pretax profits	$ 5,661	$ 5,235	$ 11,218	$ 10,395

XML

Capital Stock Repurchase Plan Transactions (Tables)

6 Months Ended

Jun. 30, 2015

Capital Stock Repurchases Plan Transactions [Abstract]

Schedule Of Capital Stock Repurchases

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Shares repurchased		250,000		300,000		250,000		682,934
Weighted average price per share	$	119.05	$	85.04	$	119.05	$	85.65

XML

Revenue Recognition (Narrative) (Details) - Jun. 30, 2015 - USD ($)	Total	Total
Revenue Recognition [Abstract]
Medicare cap reversal	$ 0	$ 165,000

XML

Segments

6 Months Ended

Jun. 30, 2015

Segments [Abstract]

Segments

3.   Segments

Service revenues and sales and after-tax earnings by business segment are as follows (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Service Revenues and Sales
VITAS	$	276,460	$	264,026	$	546,073	$	524,438
Roto-Rooter		105,461		96,156		212,500		194,044
Total	$	381,921	$	360,182	$	758,573	$	718,482
After-tax Earnings
VITAS	$	21,800	$	20,892	$	41,116	$	39,051
Roto-Rooter		12,153		10,719		24,161		20,751
Total		33,953		31,611		65,277		59,802
Corporate		(6,978)		(7,248)		(13,765)		(14,865)
Net income	$	26,975	$	24,363	$	51,512	$	44,937

We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”. 

XML

Revenue Recognition (Schedule Of Medicare Cap Liability Activity) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Revenue Recognition [Abstract]
Beginning Balance January 1,	$ 6,112	$ 8,260
2015 measurement period	(165)
2014 measurement period		(704)
Payments	(4,782)	(3,439)
Ending Balance June 30,	$ 1,165	$ 4,117

XML

Long-Term Debt (Financial Debt Covenants) (Details) - 6 months ended Jun. 30, 2015 $ in Millions	USD ($)
Long-Term Debt [Abstract]
Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA), Requirement	3.50
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges), Requirement	1.50
Annual Operating Lease Commitment, Requirement	$ 50.0

XML

Consolidated Balance Sheet - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 32,705	$ 14,132
Accounts receivable less allowances of $17,156 (2014 - $14,728)	119,116	124,607
Inventories	6,250	6,168
Current deferred income taxes	16,432	15,414
Prepaid income taxes	3,474	2,787
Prepaid expenses	12,069	11,456
Total current assets	190,046	174,564
Investments of deferred compensation plans	51,940	49,147
Properties and equipment, at cost, less accumulated depreciation of $190,227 ( 2014 - $185,735)	107,556	105,336
Identifiable intangible assets less accumulated amortization of $33,031 (2014 - $32,772)	55,979	56,027
Goodwill	472,546	466,722
Other assets	7,216	8,136
Total Assets	885,283	859,932
Current liabilities
Accounts payable	39,327	46,849
Current portion of long-term debt	7,500	6,250
Income taxes	20	5,818
Accrued insurance	42,589	40,814
Accrued compensation	48,909	50,718
Accrued legal	1,815	753
Other current liabilities	21,752	24,352
Total current liabilities	161,912	175,554
Deferred income taxes	28,280	29,945
Long-term debt	152,500	141,250
Deferred compensation liabilities	52,051	48,684
Other liabilities	12,742	13,143
Total Liabilities	$ 407,485	$ 408,576
Commitments and contingencies
STOCKHOLDERS' EQUITY
Capital stock - authorized 80,000,000 shares $1 par; issued 33,619,982 shares (2014 - 33,337,297 shares)	$ 33,620	$ 33,337
Paid-in capital	562,654	538,845
Retained earnings	815,229	771,176
Treasury stock - 16,800,313 shares (2014 - 16,446,572)	(936,056)	(894,285)
Deferred compensation payable in Company stock	2,351	2,283
Total Stockholders' Equity	477,798	451,356
Total Liabilities and Stockholders' Equity	$ 885,283	$ 859,932

XML

Retirement Plans (Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Retirement Plans [Abstract]
Defined contribution plans expense	$ 2,991	$ 3,324	$ 7,178	$ 7,222

XML

Basis Of Presentation

6 Months Ended

Jun. 30, 2015

Basis Of Presentation [Abstract]

Basis Of Presentation

1.   Basis of Presentation

As used herein, the terms "We," "Company" and "Chemed" refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries. 

We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X.  Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The                December 31, 2014 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP.  However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows.  These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2014. 

XML

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Excluded stock options	411,000	0	411,000	0
Shares issued in conjunction with the conversion feature of the Notes		249,000		249,000
Dilutive impact of the warrants		121,000		202,000
Senior Convertible Notes [Member]
Interest rate of senior convertible notes		1.875%		1.875%

XML

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2015

Revenue Recognition [Abstract]

Schedule Of Medicare Cap Liability Activity

	June 30,
	2015		2014
Beginning balance January 1,	$	6,112	$	8,260
2015 measurement period		(165)		-
2014 measurement period		-		(704)
Payments		(4,782)		(3,439)
Ending balance June 30,	$	1,165	$	4,117

Schedule Of Cost Of Charity Care

Three months ended June 30,				Six months ended June 30,
2015			2014	2015		2014
$	1,885	$	1,931	$	3,859	$	3,630

XML

Earnings Per Share (Schedule Of Computation Of Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Earnings, Income	$ 26,975	$ 24,363	$ 51,512	$ 44,937
Diluted earnings, Income	$ 26,975	$ 24,363	$ 51,512	$ 44,937
Earnings per Share	$ 1.60	$ 1.41	$ 3.05	$ 2.59
Earnings per Share, Diluted	$ 1.55	$ 1.36	$ 2.96	$ 2.48
Net Income, Earnings, Shares	16,880	17,236	16,872	17,374
Dilutive stock options, Shares	390	376	395	374
Nonvested stock awards, Shares	149	147	152	147
Conversion of Notes, Shares		121		202
Net Income, Diluted Earnings, Shares	17,419	17,880	17,419	18,097

XML

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Schedule Of Computation Of Earnings Per Share

			Net Income
For the Three Months Ended June 30,		Income		Shares	Earnings per Share
2015
	Earnings	$	26,975	16,880	$	1.60
	Dilutive stock options		-	390
	Nonvested stock awards		-	149
	Diluted earnings	$	26,975	17,419	$	1.55
2014
	Earnings	$	24,363	17,236	$	1.41
	Dilutive stock options		-	376
	Nonvested stock awards		-	147
	Conversion of notes		-	121
	Diluted earnings	$	24,363	17,880	$	1.36

			Net Income
For the Six Months Ended June 30,		Income		Shares	Earnings per Share
2015
	Earnings	$	51,512	16,872	$	3.05
	Dilutive stock options		-	395
	Nonvested stock awards		-	152
	Diluted earnings	$	51,512	17,419	$	2.96
2014
	Earnings	$	44,937	17,374	$	2.59
	Dilutive stock options		-	374
	Nonvested stock awards		-	147
	Conversion of Notes		-	202
	Diluted earnings	$	44,937	18,097	$	2.48

XML

Revenue Recognition

6 Months Ended

Jun. 30, 2015

Revenue Recognition [Abstract]

Revenue Recognition

2.   Revenue Recognition

Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed.  Generally, this occurs when services are provided or products are delivered.  VITAS recognizes revenue at the estimated realizable amount due from third-party payers.  Medicare payments are subject to certain limitations, as described below.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”).  Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions.  However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to patient revenue. 

During the second quarter of 2015, no Medicare cap was recorded.

During the first six months ended June 30, 2015, we recorded a $165,000 Medicare cap reversal of amounts recorded in the fourth quarter of 2014 for one program’s projected 2015 measurement period liability.  The fourth quarter of 2014 was part of the 2015 Medicare cap year.

Shown below is the Medicare cap liability activity for the fiscal periods ended (in thousands):

	June 30,
	2015		2014
Beginning balance January 1,	$	6,112	$	8,260
2015 measurement period		(165)		-
2014 measurement period		-		(704)
Payments		(4,782)		(3,439)
Ending balance June 30,	$	1,165	$	4,117

Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient does not have the financial wherewithal to make payment.  There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care.  The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care.  The cost of charity care is as follows (in thousands):

Three months ended June 30,				Six months ended June 30,
2015			2014	2015		2014
$	1,885	$	1,931	$	3,859	$	3,630

XML

Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Consolidated Balance Sheet [Abstract]
Accounts receivable, allowances	$ 17,156	$ 14,728
Properties and equipment, accumulated depreciation	190,227	185,735
Identifiable intangible assets, accumulated amortization	$ 33,031	$ 32,772
Capital stock - authorized	80,000,000	80,000,000
Capital stock - par value	$ 1	$ 1
Capital stock - issued	33,619,982	33,337,297
Treasury stock	16,800,313	16,446,572

XML

Cash Overdrafts And Cash Equivalents

6 Months Ended

Jun. 30, 2015

Cash Overdrafts And Cash Equivalents [Abstract]

Cash Overdrafts And Cash Equivalents

12.   Cash Overdrafts and Cash Equivalents

Included in accounts payable at June 30, 2015 is cash overdrafts payable of $3.7 million (December 31, 2014 - $10.5 million).

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds.  We had          $66,000 in cash equivalents as of June 30, 2015.  There was $80,000 in cash equivalents as of December 31, 2014.  The weighted average rate of return for our cash equivalents was 0.08% at June 30, 2015 and 0.06% at December 31, 2014.

XML

Document And Entity Information - Jun. 30, 2015 - shares	Total
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2015
Entity Registrant Name	CHEMED CORP
Trading Symbol	CHE
Entity Central Index Key	0000019584
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	16,919,487

XML

Financial Instruments

6 Months Ended

Jun. 30, 2015

Financial Instruments [Abstract]

Financial Instruments

13.   Financial Instruments

FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements.  Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities.  Level 2 measurements use significant other observable inputs.  Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions.  In recording the fair value of assets and liabilities, companies must use the most reliable measurement available. 

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of          

June 30, 2015 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	51,940	$	51,940	$	-	$	-
Long-term debt		160,000		-		160,000		-

For the mutual fund investments carrying value is fair value.  All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of      December 31, 2014 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	49,147	$	49,147	$	-	$	-
Long-term debt		147,500		-		147,500		-

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments.

XML

Consolidated Statement Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Consolidated Statement Of Income [Abstract]
Service revenues and sales	$ 381,921	$ 360,182	$ 758,573	$ 718,482
Cost of services provided and goods sold (excluding depreciation)	270,663	257,007	539,548	514,826
Selling, general and administrative expenses	57,994	53,649	116,582	109,320
Depreciation	8,082	7,272	16,114	14,421
Amortization	582	735	1,158	1,744
Total costs and expenses	337,321	318,663	673,402	640,311
Income from operations	44,600	41,519	85,171	78,171
Interest expense	(969)	(2,429)	(1,938)	(6,244)
Other income - net	536	756	1,099	1,572
Income before income taxes	44,167	39,846	84,332	73,499
Income taxes	(17,192)	(15,483)	(32,820)	(28,562)
Net income	$ 26,975	$ 24,363	$ 51,512	$ 44,937
Earnings Per Share
Net income	$ 1.60	$ 1.41	$ 3.05	$ 2.59
Average number of shares outstanding	16,880	17,236	16,872	17,374
Diluted Earnings Per Share
Net income	$ 1.55	$ 1.36	$ 2.96	$ 2.48
Average number of shares outstanding	17,419	17,880	17,419	18,097
Cash Dividends Per Share	$ 0.22	$ 0.20	$ 0.44	$ 0.40

XML

Stock-Based Compensation Plans

6 Months Ended

Jun. 30, 2015

Stock-Based Compensation Plans [Abstract]

Stock-Based Compensation Plans

7.   Stock-Based Compensation Plans

On May 18, 2015, the Compensation/Incentive Committee of the Board of Directors (“CIC”) approved a grant of 32,550 shares of restricted stock to certain key employees.  The restricted shares vest ratably over three years from the date of issuance.  The cumulative compensation expense related to the restricted stock award is $4.0 million and will be recognized over the three-year vesting period.  We assumed no forfeitures in determining the cumulative compensation expense of the grant.

On February 20, 2015, the (“CIC”) granted 10,761 Performance Stock Units (“PSUs”) contingent upon the achievement of certain total shareholders return (“TSR”) targets as compared to the TSR of a group of peer companies for the three-year period ending December 31, 2017, the date at which such awards vest.  The cumulative compensation cost of the TSR-based PSU award to be recorded over the three year service period is $1.5 million.

On February 20, 2015, the CIC also granted 10,761 PSUs contingent upon the achievement of certain earnings per share (“EPS”) targets for the three-year period ending December 31, 2017.  At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records that expense over the service period of the award.  We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three year service period is $1.6 million.

XML

Other Income - Net

6 Months Ended

Jun. 30, 2015

Other Income - Net [Abstract]

Other Income - Net

6.   Other Income – Net

Other income -- net comprises the following (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Market value gains on assets held in deferred
compensation trust	$	498	$	650	$	1,448	$	1,812
Loss on disposal of property and equipment		(63)		(48)		(15)		(326)
Interest income - net		86		58		130		8
Other - net		15		96		(464)		78
Total other income - net	$	536	$	756	$	1,099	$	1,572

XML

Segments (Tables)

6 Months Ended

Jun. 30, 2015

Segments [Abstract]

Service Revenues And Sales And After-Tax Earnings By Business Segment

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Service Revenues and Sales
VITAS	$	276,460	$	264,026	$	546,073	$	524,438
Roto-Rooter		105,461		96,156		212,500		194,044
Total	$	381,921	$	360,182	$	758,573	$	718,482
After-tax Earnings
VITAS	$	21,800	$	20,892	$	41,116	$	39,051
Roto-Rooter		12,153		10,719		24,161		20,751
Total		33,953		31,611		65,277		59,802
Corporate		(6,978)		(7,248)		(13,765)		(14,865)
Net income	$	26,975	$	24,363	$	51,512	$	44,937

XML

Capital Stock Repurchases Plan Transactions

6 Months Ended

Jun. 30, 2015

Capital Stock Repurchases Plan Transactions [Abstract]

Capital Stock Repurchases Plan Transactions

14.   Capital Stock Repurchase Plan Transactions

We repurchased the following capital stock for the three and six months ended June 30, 2015 and 2014:

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Shares repurchased		250,000		300,000		250,000		682,934
Weighted average price per share	$	119.05	$	85.04	$	119.05	$	85.65

In March 2015, the Board of Directors authorized an additional $100 million for stock repurchase under Chemed’s existing share repurchase program. We currently have $82.0  million of authorization remaining under this share repurchase plan.

XML

Legal And Regulatory Matters

6 Months Ended

Jun. 30, 2015

Legal And Regulatory Matters [Abstract]

Legal And Regulatory Matters

10.  Legal and Regulatory Matters

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

Regulatory Matters and Litigation

In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas,  United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a then registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”).  Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action.  The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS.  The defendants filed a motion to dismiss on September 24, 2013.  The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014. 

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California,United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government partially intervened in Gonzales.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.  

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the Spottiswood,  Urick, and  Gonzales complaints with the 2013 Action.  As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes.  The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators.  The Spottiswood relator filed an action under the Illinois False Claims Act, The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014.  The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters.  In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.  In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

The costs incurred related to U.S. v. Vitas and related regulatory matters were $1.4 million and $410,000 for the quarters ended June 30, 2015 and 2014, respectively. For the six months ended June 30, 2015 and 2014, the net costs were $2.7 million and $1.2 million respectively.

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance.  On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al., No. 13 Civ. 1854 (LPS) (D. Del.).  It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant.  Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare.  The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. 

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al., No. 13 Civ. 833 (MDB) (S.D. Ohio).  She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant.  Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS

to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls.  The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants.  The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole.  Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. 

On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6).  On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware.  Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke. 

On October 15, 2014, Plaintiff KBC filed a motion to consolidate KBC with North.  On February 2, 2015 the court granted the motion for consolidation in full, appointing Plaintiff KBC the sole lead plaintiff and its counsel, the sole lead and liaison counsel.  The court ordered that both cases will proceed under the caption In re Chemed Corp. Shareholder and Derivative Litigation, No. 13 Civ. 1854 (LPS) (CJB) (D. Del.).  Plaintiff KBC has designated its pending complaint as the operative complaint in the consolidated proceedings.  Defendants have renewed their motion to dismiss the claims and allegations. 

The Company intends to defend vigorously against the allegations in each of the above lawsuits.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity.  Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

XML

Independent Contractor Operations

6 Months Ended

Jun. 30, 2015

Independent Contractor Operations [Abstract]

Independent Contractor Operations

8.   Independent Contractor Operations

The Roto-Rooter segment sublicenses with 69 independent contractors to operate certain plumbing repair and drain cleaning businesses in lesser-populated areas of the United States and Canada.  We had notes receivable from our independent contractors as of June 30, 2015 totaling $1.6 million (December 31, 2014 - $1.6 million).  In most cases these loans are fully or partially secured by equipment owned by the contractor.  The interest rates on the loans range from 0% to 7% per annum and the remaining terms of the loans range from 2 months to 5 years at June 30, 2015.  We recorded the following from our independent contractors (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Revenues	$	9,527	$	9,190	$	18,991	$	18,213
Pretax profits		5,661		5,235		11,218		10,395

XML

Retirement Plans

6 Months Ended

Jun. 30, 2015

Retirement Plans [Abstract]

Retirement Plans

9.   Retirement Plans

All of the Company’s plans that provide retirement and similar benefits are defined contribution plans.  These expenses include the impact of market gains and losses on assets held in deferred compensation plans.  Expenses for the Company’s pension and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):

Three months ended June 30,				Six months ended June 30,
2015		2014		2015		2014
$	2,991	$	3,324	$	7,178	$	7,222

XML

Concentration Of Risk

6 Months Ended

Jun. 30, 2015

Concentration Of Risk [Abstract]

Concentration Of Risk

11.   Concentration of Risk

VITAS has pharmacy services agreements ("Agreements") with Omnicare, Inc. and its subsidiaries (“OCR”) whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR.  The Agreements renew automatically for three-year terms.  Either party may cancel the Agreements at the end of any term by giving 30 days prior written notice.  VITAS made purchases from OCR of        $9.5 million and $8.8 million for the three months ended June 30, 2015 and 2014, respectively.  VITAS made purchases from OCR of $18.7 million and $17.7 million for the six months ended June 30, 2015 and 2014, respectively. For the three and six month periods ending June 30, 2015 and 2014, respectively, purchases from this vendor exceed90% of all pharmacy services used by VITAS.

XML

Segments (Service Revenues And Sales And After-Tax Earnings By Business Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Total service revenues and sales	$ 381,921	$ 360,182	$ 758,573	$ 718,482
Net income	26,975	24,363	51,512	44,937
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total service revenues and sales	381,921	360,182	758,573	718,482
Net income	33,953	31,611	65,277	59,802
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Net income	(6,978)	(7,248)	(13,765)	(14,865)
Segment VITAS [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total service revenues and sales	276,460	264,026	546,073	524,438
Net income	21,800	20,892	41,116	39,051
Segment Roto-Rooter [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total service revenues and sales	105,461	96,156	212,500	194,044
Net income	$ 12,153	$ 10,719	$ 24,161	$ 20,751

XML

Business Combinations (Narrative) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2015 USD ($) item	Jun. 30, 2014 USD ($)
Business Acquisition [Line Items]
Business combinations | $	$ 6,614	$ 250
Segment Roto-Rooter [Member]
Business Acquisition [Line Items]
Number of Business Combinations	2

XML

Business Combinations

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Business Combinations

16.   Business Combinations

In the first six months of 2015, we completed two business combinations within our Roto-Rooter segment for $6.6 million in cash to increase our market penetration in Omaha, Nebraska and Scranton, Pennsylvania.  A substantial portion of this aggregate purchase price was allocated to goodwill.  The operating results of these business combinations have been included in our results of operations since the acquisition date and are not material for the three and six-month periods ended June 30, 2015 nor for the comparable prior year periods.

XML

Other Income - Net (Tables)

6 Months Ended

Jun. 30, 2015

Other Income - Net [Abstract]

Schedule Of Other Income - Net

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Market value gains on assets held in deferred
compensation trust	$	498	$	650	$	1,448	$	1,812
Loss on disposal of property and equipment		(63)		(48)		(15)		(326)
Interest income - net		86		58		130		8
Other - net		15		96		(464)		78
Total other income - net	$	536	$	756	$	1,099	$	1,572

XML

Financial Instruments (Carrying Value, Fair Value And Hierarchy Of Financial Instruments) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mutual fund investments of deferred compensation plans held in trust	$ 51,940	$ 49,147
Long-term debt and current portion of long-term debt	160,000	147,500
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mutual fund investments of deferred compensation plans held in trust	51,940	49,147
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt and current portion of long-term debt	$ 160,000	$ 147,500

XML

Other Income - Net (Schedule Of Other Income - Net) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Other Income - Net [Abstract]
Market value gains on assets held in deferred compensation trust	$ 498	$ 650	$ 1,448	$ 1,812
Loss on disposal of property and equipment	(63)	(48)	(15)	(326)
Interest income - net	86	58	130	8
Other - net	15	96	(464)	78
Total other income - net	$ 536	$ 756	$ 1,099	$ 1,572

XML

Consolidated Statement Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows from Operating Activities
Net income	$ 51,512	$ 44,937
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	17,272	16,165
Deferred income taxes	(2,783)	6,180
Provision for uncollectible accounts receivable	7,734	6,449
Amortization of discount on convertible notes		3,392
Stock option expense	2,787	2,453
Amortization of debt issuance costs	262	564
Noncash long-term incentive compensation	2,391	986
Changes in operating assets and liabilities, excluding amounts acquired in business combinations:
Increase in accounts receivable	(2,182)	(6,782)
Increase in inventories	(78)	(153)
Increase in prepaid expenses	(507)	(3,301)
Decrease in accounts payable and other current liabilities	(1,314)	(33,584)
Increase/(decrease) in income taxes	(2,384)	7,224
Increase in other assets	(2,229)	(2,748)
Increase in other liabilities	2,966	4,644
Excess tax benefit on share-based compensation	(3,998)	(1,866)
Other sources	189	553
Net cash provided by operating activities	69,638	45,113
Cash Flows from Investing Activities
Capital expenditures	(18,846)	(19,454)
Business combinations, net of cash acquired	(6,614)	(250)
Other sources	395	192
Net cash used by investing activities	(25,065)	(19,512)
Cash Flows from Financing Activities
Proceeds from revolving line of credit	103,200	245,500
Payments on revolving line of credit	(88,200)	(185,500)
Payments on other long-term debt	(2,500)	(186,956)
Proceeds from other long-term debt		100,000
Purchases of treasury stock	(29,762)	(58,493)
Proceeds from exercise of stock options	8,044	16,092
Dividends paid	(7,459)	(6,757)
Capital stock surrendered to pay taxes on stock-based compensation	(5,876)	(3,543)
Retirement of warrants		(2,645)
Excess tax benefit on share-based compensation	3,998	1,866
Debt issuance costs		(939)
Decrease in cash overdrafts payable	(6,791)	(479)
Other uses	(654)	(252)
Net cash used by financing activities	(26,000)	(82,106)
Increase/(decrease) in cash and cash equivalents	18,573	(56,505)
Cash and cash equivalents at beginning of period	14,132	84,418
Cash and cash equivalents at end of period	$ 32,705	$ 27,913

XML

Long-Term Debt

6 Months Ended

Jun. 30, 2015

Long-Term Debt [Abstract]

Long-Term Debt

5.   Long-Term Debt

On June 30, 2014, we replaced our existing credit agreement with the Third Amended and Restated Credit Agreement (“2014 Credit Agreement”).  Terms of the 2014 Credit Agreement consist of a five-year, $350 million revolving credit facility and a $100 million term loan.  The 2014 Credit Agreement has a floating interest rate that is currently LIBOR plus 113 basis points. 

The debt outstanding as of June 30, 2015 consists of the following:

Revolver	$	65,000
Term loan		95,000
Total		160,000
Current portion of term and revolving loan		(7,500)
Long-term debt	$	152,500

Scheduled principal payments of the term loan are as follows:

2015	$	3,750
2016		7,500
2017		8,750
2018		10,000
2019		65,000
	$	95,000

The 2014 Credit Agreement contains the following quarterly financial covenants:

Description	Requirement
Leverage Ratio (Consolidated Indebtedness/Consolidated  Adj. EBITDA)	<  3.50 to 1.00
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges)	>  1.50 to 1.00
Annual Operating Lease Commitment	<  $50.0 million

We are in compliance with all debt covenants as of June 30, 2015. We have issued $36.6 million in standby letters of credit as of June 30, 2015 for insurance purposes.  Issued letters of credit reduce our available credit under the 2014 Credit Agreement.  As of June 30, 2015, we have approximately $248.4 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility.

XML

Independent Contractor Operations (Tables)

6 Months Ended

Jun. 30, 2015

Independent Contractor Operations [Abstract]

Schedule Of Independent Contractors

	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Revenues	$	9,527	$	9,190	$	18,991	$	18,213
Pretax profits		5,661		5,235		11,218		10,395

XML

Long-Term Debt (Debt Outstanding) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Total	$ 160,000
Current portion of term loan and revolving loan	(7,500)	$ (6,250)
Long-term debt	152,500	$ 141,250
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total	65,000
Medium-term Notes [Member]
Debt Instrument [Line Items]
Total	$ 95,000

XML

Recent Accounting Statements

6 Months Ended

Jun. 30, 2015

Recent Accounting Statements [Abstract]

Recent Accounting Statements

15.   Recent Accounting Statements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers” which provides additional guidance to clarify the principles for recognizing revenue.  The standard will also be used to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide more useful information to users through improved disclosure requirements, and simplify the preparation of financial statements.  The guidance is effective for fiscal years beginning after December 15, 2017.  We are currently evaluating the impact of this ASU on our existing revenue recognition policies and disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ASU No. 2014-15 - Presentation of Financial Statements-Going Concern”.   ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for us for the annual period ending December 31, 2016 and interim periods thereafter. We do not expect the adoption of this standard to have a material impact on our consolidated financial position, results of operations or cash flows.

In April 2015, the FASB issued Accounting Standards Update No. 2015-03, “ASU No. 2015-03 – Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”.  ASU 2015-03 is intended to simplify the presentation of debt issuance costs.  Under the new guidance, debt issuance costs will be presented as a direct deduction from the carrying value of the associated debt, consistent with the existing presentation of a debt discount.  This guidance is effective for us for the annual period beginning after December 15, 2015.  We do not expect the adoption of this standard to have a material impact on our consolidated financial position, results of operations or cash flows.